Download Free Immunotherapy In Resistant Cancer From The Lab Bench Work To Its Clinical Perspectives Book in PDF and EPUB Free Download. You can read online Immunotherapy In Resistant Cancer From The Lab Bench Work To Its Clinical Perspectives and write the review.

Immunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical Perspectives provides high level knowledge on detailed mechanisms of actions and biological interactions of different immune drugs, with an aim of offering researchers and clinicians cutting-edge therapies to overcome drug resistance. The book explains the latest immunotherapies for different types of cancer, helping users carry out research projects or create alternatives for drug development in the pharmaceutical industry. Topics discussed include the relationship between immunotherapy and macrophages, immune checkpoints in different types of cancer, immune cocktails in solid tumors, and immune-phenotyping. Additionally, the book presents basic and clinical data on immunoresistance and glycosylation. This book is a valuable source for cancer researchers, medical doctors, clinicians and members of the biomedical field who must understand certain mechanisms to fight cancer that is resistant to immunotherapy. - Provides basic and clinical evidence based on molecular interactions and clinical studies to address the risks and benefits of cancer immunotherapy - Presents the results of new immunotherapy trials, discussing the state-of-the-art in different types of cancer - Discusses targeted therapies approved by the FDA, along with therapies with clinical potential used in basic studies
NK Cells in Cancer Immunotherapy: Successes and Challenges explains the latest immunotherapeutic strategies, focusing on NK cells to allow the best and precise combination treatments to cancer patients. The book provides existing background knowledge in the field of immunotherapy and discusses future areas of research required to carry out cutting-edge, validated therapies. Chapters cover advances in immunotherapeutic strategies, in particular, the use of NK cells with and without T-cell therapy in the treatment of cancer. The book is a valuable resource for cancer researchers, oncologists, graduate students and those interested in learning more about novel strategies to treat cancer patients. Immunotherapy is fast becoming the method of choice for cancer therapy. Although remarkable advances have been made in the field of immunotherapy, there are significant challenges and difficulties ahead since many of the current immunotherapeutic strategies do not provide long-lasting treatment strategies, and therefore are not very effective. - Covers CAR/T and CAR/NK and adoptive NK cell therapy with and without T cell therapies - Discusses basic biology of NK cells and mouse models of human cancers and the role of NK cells in metastatic cancer and in cancer stem cells - Encompasses information on combination therapies using check point inhibition, adoptive transfer of cytotoxic effector cells, chemotherapeutic drugs and activating and inhibitory antibodies
Immune landscape of pancreatic cancer development and drug resistance explores the advances in immune-based therapies aimed at harnessing the power of the immune system against pancreatic cancer and rewiring tumor microenvironments to eradicate pancreatic cells. With a strong focus on the development of therapeutic methods to improve the survival rates of pancreatic cancer, this book also shows the latest trends in immune targeted approaches for pancreatic cancer treatment. In 12 chapters Immune landscape of pancreatic cancer development and drug resistance discusses the current understanding of PC development and its various mutational and immune features and explore some of the new immune-based therapies aimed at targeting pancreatic cancer. It covers the urgent need for developing novel therapeutic modalities and aims at delineating future fields and avenues of research in pancreatic cancer treatment. The book provides the reader with an updated understanding of the immune landscape of PC and an all-encompassing overview of the latest trends in immune targeted approaches for PC treatment. This book is a valuable resource for health professionals, scientists and researchers, students, and all those who wish to broaden their knowledge of the advances in immunotherapy in pancreatic cancer. - Summarizes the potential combination strategies and latest clinical trials in pancreatic cancer - Provides an in-depth overview of our current understanding of pancreatic cancer development, including its mutational and immune features - Explores some of the new immune-based therapies aimed at targeting PC - Shows pancreatic cancer progression and basic elements in tumor microenvironments and their role in PC progression, also covering immunotherapy strategies
Principles of Immunotherapy in Breast and Gastrointestinal Cancers: Activity, Mechanisms of Resistance and New Sensitization Strategies presents updated research findings on immunotherapy, with special focus on the mechanisms of resistance of those cancer types and how to overcome them. The book discusses topics such as tumor cell-intrinsic and extrinsic mechanisms of cancer resistance to immunotherapy; the role of currently available biomarkers; strategies to overcome therapeutic resistance; sensitizing agents for cancer resistance to cell mediated immunotherapy; and Immunotherapeutic approaches, mechanisms of resistance and sensitizing strategies in gastroesophageal and biliopancreatic tumors and colorectal cancer. It is a valuable resource for researchers, students and members of the biomedical and medical fields who want to learn more about resistance to immunotherapy and how to overcome it. - Presents relevant findings on immunotherapy for breast and GI cancer types in a synthetic and didactic way for easy consult - Describes resistance mechanisms of those cancer types and how to overcome them to improve immunotherapy outcomes - Encompasses several diagrams and figures to help readers get a clearer picture of the research findings and how they can be applied to the clinical setting
Immunotherapeutic Strategies for the Treatment of Glioma provides a review of the current state of immunotherapy for primary brain tumors. The topic is of interest to patients, clinicians, and researchers alike, particularly given the recent failure of large clinical trials. This book serves as an overview of the most promising approaches in the field and provides a foundation for considering novel and combination therapies moving forward.The book discusses several types of immunotherapies for glioma, such as peptide, dendritic cell and heat shock protein vaccines; immune checkpoint blockade; myeloid cells as target; oncolytic viruses; and CAR T cell therapy. Additionally, it discusses the mechanisms of immune suppression in patients and immunogenomics.This volume is a valuable source for cancer researchers, oncologists and several members of biomedical field who are interested in novel strategies to fight glioblastoma. - Summarizes the work in immunotherapy for glioma to-date, including the available evidence from preclinical studies and clinical trials - Reviews the challenges and successes of the most promising strategies for brain tumor immunotherapy - Provides a foundation for considering novel and combination therapies moving forward
In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients.
The interplay between tumors and their immunologic microenvironment is complex, difficult to decipher, but its understanding is of seminal importance for the development of novel prognostic markers and therapeutic strategies. The present review discusses tumor-immune interactions in several human cancers that illustrate various aspects of this complexity and proposes an integrated scheme of the impact of local immune reactions on clinical outcome. Current active immunotherapy trials have shown durable tumor regressions in a fraction of patients. However, clinical efficacy of current vaccines is limited, possibly because tumors skew the immune system by means of myeloid-derived suppressor cells, inflammatory type 2 T cells and regulatory T cells (Tregs), all of which prevent the generation of effector cells. To improve the clinical efficacy of cancer vaccines in patients with metastatic disease, we need to design novel and improved strategies that can boost adaptive immunity to cancer, help overcome Tregs and allow the breakdown of the immunosuppressive tumor microenvironment.
Gene therapy has the potential to be a tailor-made therapeutic with increased specificity and decreased side effects that can offer a "cure" for many disorders. The aim of this book is to provide up-to-date reviews of the rapidly growing field of gene therapy. Chapters cover a large range of topics including methods of gene delivery, and identification of targets with several papers on cancer gene therapy. If more people become aware of the true nature and potential of gene therapy, perhaps we can achieve the full benefit of such an innovative approach for the treatment of a range of diseases, including cancer.
Winner of the Pulitzer Prize and a documentary from Ken Burns on PBS, this New York Times bestseller is “an extraordinary achievement” (The New Yorker)—a magnificent, profoundly humane “biography” of cancer—from its first documented appearances thousands of years ago through the epic battles in the twentieth century to cure, control, and conquer it to a radical new understanding of its essence. Physician, researcher, and award-winning science writer, Siddhartha Mukherjee examines cancer with a cellular biologist’s precision, a historian’s perspective, and a biographer’s passion. The result is an astonishingly lucid and eloquent chronicle of a disease humans have lived with—and perished from—for more than five thousand years. The story of cancer is a story of human ingenuity, resilience, and perseverance, but also of hubris, paternalism, and misperception. Mukherjee recounts centuries of discoveries, setbacks, victories, and deaths, told through the eyes of his predecessors and peers, training their wits against an infinitely resourceful adversary that, just three decades ago, was thought to be easily vanquished in an all-out “war against cancer.” The book reads like a literary thriller with cancer as the protagonist. Riveting, urgent, and surprising, The Emperor of All Maladies provides a fascinating glimpse into the future of cancer treatments. It is an illuminating book that provides hope and clarity to those seeking to demystify cancer.
This book systematically reviews the most important findings on cancer immune checkpoints, sharing essential insights into this rapidly evolving yet largely unexplored research topic. The past decade has seen major advances in cancer immune checkpoint therapy, which has demonstrated impressive clinical benefits. The family of checkpoints for mediating cancer immune evasion now includes CTLA-4, PD-1/PD-L1, CD27/CD70, FGL-1/LAG-3, Siglec-15, VISTA (PD-1L)/VSIG3, CD47/SIRPA, APOE/LILRB4, TIGIT, and many others. Despite these strides, most patients do not show lasting remission, and some cancers have been completely resistant to the therapy. The potentially lethal adverse effects of checkpoint blockade represent another major challenge, the mechanisms of which remain poorly understood. Compared to the cancer signaling pathways, such as p53 and Ras, mechanistic studies on immune checkpoint pathways are still in their infancy. To improve the responses to checkpoint blockade therapy and limit the adverse effects, it is essential to understand the molecular regulation of checkpoint molecules in both malignant and healthy cells/tissues. This book begins with an introduction to immune checkpoint therapy and its challenges, and subsequently describes the regulation of checkpoints at different levels. In closing, it discusses recent therapeutic developments based on mechanistic findings, and outlines goals for future translational studies. The book offers a valuable resource for researchers in the cancer immunotherapy field, helping to form a roadmap for checkpoint regulation and develop safer and more effective immunotherapies.